Skip to main content

Table 1 Baseline data and outcome variables in 15 patients treated with ezetimibe for 8 weeks

From: Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial

Variables Baseline Treatment % change P*
Dietary assessment     
Total calories (kj/d) 8037 [6728–9033] 7657 [6841–11167] -4.7% .55
Total fat (g/d) 93 [76–105] 86 [83–115] -7.5% .53
Saturated fatty acids (g/d) 26 [17–31] 24 [19–32] -7.7% .94
Cholesterol (mg/d) 254 [223–340] 294 [247–346] 15.7 .81
Phytosterols (mg/d) 184 [141–211] 156 [129–193] -15.2% .09
Body weight (kg) 73.0 [61.2-80.1] 73.1 [63.9-80.8] 0.1% 1
Waist circumference (cm) 92.5 [85.7-96] 95.0 [88–100] 2.7% .55
Lipids and apos     
Total cholesterol (mmol/L) 5.87 [5.46-6.54] 5.2 [4.89-5.61] -11.4% .002
LDL-cholesterol (mmol/L) 3.93 [3.46-4.27] 3.13 [2.95-3.44] -20.4% .003
nonHDL-cholesterol (mmol/L) 4.63 [4.29-5.30] 4.01 [3.59-4.42] -13.4% .002
HDL-cholesterol (mmol/L) 1.21 [1.11-1.47] 1.19 [1.03-1.34] -2.1% .11
Triglycerides (mmol/L) 1.64 [1.15-2.04] 1.42 [1.15-2.29] -13.1% .46
Apo A1 (g/L) 1.47 [1.39-1.53] 1.54 [1.44-1.59] 4.7% 1
Apo B (g/L) 1.21 [1.09-1.42] 1.10 [0.95-1.24] -9.1% .02
C-reactive protein (mg/L) 1.2 [0.4-1.6] 0.6 [0.5-3.5] -50% .61
Plasma viral load (copies/mL) 49 [49–49] 49 [49–49] 0% .65
CD4 cell count (cells/μL) 503 [353–802] 499 [323–794] -0.8% .65
Lathosterol (μmol/L) 7.08 [5.19-9.43] 9.97 [6.68-12.67] 40.9% .015
Lathosterol/cholesterol 1.26 [0.84-1.54] 1.93 [1.37-2.40] 53.2% .005
Campesterol (μmol/L) 27.78 [20.22-38.95] 14.78 [10.72-18.51] -46.8% .001
Campesterol/cholesterol 4.65 [3.23-6.36] 2.62 [1.98-3.53] -43.6% .001
Sitosterol (μmol/L) 22.96 [20.34-33.25] 14.77 [10.96-19.52] -35.7% .001
Sitosterol/cholesterol 4.46 [3.70-6.09] 2.59 [2.17-3.76] -41.9% .001
  1. Results are expressed as medians [IQR]. *Wilcoxon Rank test.